Topic : Tests/Procedures

Other Topics :

ASH 2016: “Room for improvement” in CML monitoring, treatment

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – A new Canadian study has examined how often people with CML are tested to determine their response to medication (Hillis and colleagues. ASH 2016; abstract 3079). Informat
Continue Reading →

ASCO 2016 – Hidden benefits of more frequent testing

During treatment for chronic myelogenous leukemia (CML), frequent tests are needed to determine how well people are responding to their medication. Key response “milestones” have identified that an earlier, more profound response translates to a better outcome over the longer term.
Continue Reading →

Transplantation: the graft vs. leukemia effect

Part 1 Part 2 Stem cell transplantation was initially conceived as a way of eliminating leukemia from the bone marrow much as surgery is used to remove solid tumours. However, the marrow needed to be replaced because it was the source of new blood cells, including immune cells, and a
Continue Reading →

What is the role of stem-cell transplants in the TKI era?

Part 1 Throughout the 1990s, stem-cell transplantation provided a possible cure for CML, but its use declined as tyrosine kinase inhibitors (TKIs) became available starting in 2001. Medications were highly effective in controlling CML, could be taken by most people, and were generally
Continue Reading →

The evolving role of transplantation in CML

Part 1 A CML therapy that emerged in the 1980s was stem-cell transplantation (SCT) (Thomas and colleagues. Ann Intern Med 1986;104:155-163). The idea was that leukemia originated in the bone marrow, so destroying the bone marrow and replacing it with new cells might cure the disease t
Continue Reading →

Key tests will diagnose CML

Doctors perform a number of tests on blood and bone samples to make the diagnosis of CML in people suspected of having the disease. The following is a summary of the tests and what they tell you.
Continue Reading →

ASH 2014: Newer treatments for CML – Part 3

Part 3 of our ASH 2014 coverage looks at novel therapies and new treatment approaches for CML.
Continue Reading →

ASH 2014: An update on stopping treatment – Part 2

Stopping treatment is perhaps the hottest topic in CML research, and a number of new studies presented at ASH 2014 looked at this issue.
Continue Reading →

New 2015 guidelines for CML

The U.S. National Comprehensive Cancer Network (NCCN) has published new guidelines for the treatment of chronic myelogenous leukemia (O’Brien and colleagues).
Continue Reading →

Deep molecular response: beyond MMR

While these standards were being developed, new laboratory techniques were enabling even more sensitive PCR testing for BCR-ABL transcripts. This opened up a new world beyond MMR – to a 4-log reduction, a 4.5-log reduction, and even a 5-log reduction.
Continue Reading →